

REFERENCES

- Alberts, B., et al. 2015. "The Innate and Adaptive Immune Systems." In *Molecular Biology of the Cell*, 1297–1342. New York: Garland Science Taylor and Francis Group.
- Andrews, N., et al. 2004. "Thimerosal Exposure in Infants and Developmental Disorders: A Retrospective Cohort Study in the United Kingdom Does Not Support a Causal Association." *Pediatrics* 114(3): 584:592. <https://doi.org/10.1542/peds.2003-1177-L>.
- Centers for Disease Control and Prevention (CDC). 2013. *Understanding Thimerosal, Mercury, and Vaccine Safety*. <https://www.cdc.gov/vaccines/hcp/conversations/downloads/vacsafe-thimerosal-color-office.pdf>.
- CDC. 2017a. *Pertussis Frequently Asked Questions*. <https://www.cdc.gov/pertussis/about/faqs.html>.
- CDC. 2017b. *Polio Elimination in the United States*. <https://www.cdc.gov/polio/us/>.
- CDC. 2017c. *2016–17 School Vaccination Coverage Report*. <https://www.cdc.gov/vaccines/imz-managers/coverage/schoolvaxview/data-reports/coverage-reports/2016-17.html>.
- CDC. 2017d. *2016 Childhood Hepatitis A Vaccination Coverage Report*. <https://www.cdc.gov/vaccines/imz-managers/coverage/childvaxview/data-reports/hepa/reports/2016.html>.
- CDC. 2017e. *National Notifiable Infectious Diseases and Conditions: United States*. <https://wonder.cdc.gov/nndss/static/2016/annual/2016-table1.html>.
- CDC. 2018a. *Who Should Not Get Vaccinated with these Vaccines?*. <https://www.cdc.gov/vaccines/vpd/should-not-vacc.html>.
- CDC. 2018b. *Polio Vaccine Effectiveness and Duration of Protection*. <https://www.cdc.gov/vaccines/vpd/polio/hcp/effectiveness-duration-protection.html>.
- CDC. 2018c. *Measles Vaccination*. <https://www.cdc.gov/measles/vaccination.html>.
- CDC. 2018d. *Seasonal Influenza Vaccine Effectiveness, 2004–2018*. <https://www.cdc.gov/flu/professionals/vaccination/effectiveness-studies.htm>.
- CDC. 2018e. *2018 Recommended Immunizations for Adults by Age in Easy-to-read Format*. <https://www.cdc.gov/vaccines/schedules/easy-to-read/adult-easyread.html>.
- CDC. 2018f. *2016 Adolescent MenACWY Vaccination Coverage Report*. <https://www.cdc.gov/vaccines/imz-managers/coverage/teenvaxview/data-reports/menacwy/reports/2016.html>.
- Children's Hospital of Philadelphia. 2018. *Vaccine Ingredients*. <https://www.chop.edu/centers-programs/vaccine-education-center/vaccine-ingredients>.
- Fanoy, E. B., et al. 2011. "Transmission of mumps virus from mumps-vaccinated individuals to close contacts." *Vaccine* 29(51): 9551–9556. <https://doi.org/10.1016/J.VACCINE.2011.09.100>.
- Fombonne, E., R. Zakarian, A. Bennett, L. Meng, and D. McLean-Heywood. 2006. "Pervasive Developmental Disorders in Montreal, Quebec, Canada: Prevalence and Links With Immunizations." *Pediatrics* 118(1): e139–e150. <https://doi.org/10.1542/peds.2005-2993>.
- Food and Drug Administration (FDA). 2018. *Vaccines Licensed for Use in the United States*. <http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm>.
- Food Safety Commission of Japan. 2007. "Evaluation Report of Food Additives: Polysorbates." http://www.fsc.go.jp/english/evaluationreports/foodadditive/polysorbate_report.pdf.
- Fox, M. 2015. *Washington Woman Is First U.S. Measles Death in 12 Years*. <https://www.nbcnews.com/health/health-news/woman-dies-measles-first-us-death-12-years-n385946>.

The issue brief "Scientific Misconceptions and Myths Perpetuated in the 2017 Texas Legislative Session," written by Melody T. Tan and Kirstin R.W. Matthews, discusses five anti-vaccination myths presented during the witness testimonies for Texas HB 2249 and HB 1124.

For the full brief, please visit <https://bit.ly/2q8Tx9C>.

- Gouma, S., et al. 2016. Severity of mumps disease is related to MMR vaccination status and viral shedding. *Vaccine* 34(16): 1868–1873. <https://doi.org/10.1016/J.VACCINE.2016.02.070>.
- Haber, P., Sejvar, J., Mikaeloff, Y., and DeStefano, F. 2009. “Vaccines and Guillain–Barré Syndrome.” *Drug Safety*, 32(4), 309–323. <https://doi.org/10.2165/00002018-200932040-00005>.
- Hviid, A., M. Stellfeld, J. Wohlfahrt, and M. Melbye. 2003. “Association Between Thimerosal-Containing Vaccine and Autism.” *JAMA* 290(13): 1763. <https://doi.org/10.1001/jama.290.13.1763>.
- Institute of Medicine (IOM). 2004. *Immunization Safety Review: Vaccines and Autism*. Washington, D.C.: National Academies Press. <https://doi.org/10.17226/10997>.
- Jackson, M. L., et al. 2017. “Influenza Vaccine Effectiveness in the United States during the 2015–2016 Season.” *New England Journal of Medicine* 377(6): 534–543. <https://doi.org/10.1056/NEJMoa1700153>.
- Kawai, A. T., et al. 2014. “Absence of associations between influenza vaccines and increased risks of seizures, Guillain–Barré syndrome, encephalitis, or anaphylaxis in the 2012–2013 season.” *Pharmacoepidemiology and Drug Safety* 23(5): 548–553. <https://doi.org/10.1002/pds.3575>.
- Kim, T. H., J. Johnstone, and M. Loeb. 2011. “Vaccine herd effect.” *Scandinavian Journal of Infectious Diseases* 43(9): 683–9. <https://doi.org/10.3109/00365548.2011.582247>.
- Kroger, A., C. Sumaya, L. Pickering, and W. Atkinson. 2011. “General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP).” <https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm>.
- Lane, J. M. 2006. “Mass vaccination and surveillance/containment in the eradication of smallpox.” *Current Topics in Microbiology and Immunology* 304: 17–29. https://doi.org/10.1007/3-540-36583-4_2.
- Leung, J., S. R. Bialek, and M. Marin. 2015. “Trends in varicella mortality in the United States: Data from vital statistics and the national surveillance system.” *Human Vaccines & Immunotherapeutics* 11(3): 662–8. <https://doi.org/10.1080/21645515.2015.1008880>.
- Lopez, A. S., J. Zhang, C. Brown, and S. Bialek. 2011. “Varicella-Related Hospitalizations in the United States, 2000–2006: The 1-Dose Varicella Vaccination Era.” *PEDIATRICS* 127(2): 238–245. <https://doi.org/10.1542/peds.2010-0962>.
- Marin, M., J. X. Zhang, and J. F. Seward. 2011. “Near Elimination of Varicella Deaths in the US After Implementation of the Vaccination Program.” *PEDIATRICS* 128(2): 214–220. <https://doi.org/10.1542/peds.2010-3385>.
- Matthews, Kirstin R.W., and Melody T. Tan. 2018. *Medical Freedom, Privacy, and Fear of Discrimination: The 2017 Texas Legislative Session Anti-vaccine Arguments*. Issue brief no. 10.22.18. Rice University’s Baker Institute for Public Policy, Houston, Texas. <https://bit.ly/2q3uNj0>.
- Mayo Clinic. 2018. *Measles*. <https://www.mayoclinic.org/diseases-conditions/measles/symptoms-causes/syc-20374857>.
- Mitkus, R. J., et al. 2011. “Updated aluminum pharmacokinetics following infant exposures through diet and vaccination.” *Vaccine* 29(51): 9538–9543. <https://doi.org/10.1016/J.VACCINE.2011.09.124>.
- NASEM (The National Academies of Sciences, Engineering, Medicine). 2003. *Immunization Safety Review*:

- Vaccinations and Sudden Unexpected Death in Infancy.* <http://www.nationalacademies.org/hmd/Reports/2003/Immunization-Safety-Review-Vaccinations-and-Sudden-Unexpected-Death-in-Infancy.aspx>.
- Nathanson, N., and O. M. Kew. 2010. "From emergence to eradication: the epidemiology of poliomyelitis deconstructed." *American Journal of Epidemiology* 172(11): 1213–29. <https://doi.org/10.1093/aje/kwq320>.
- Nóbrega, M. E. B., et al. 2018. "Surto de síndrome de Guillain-Barré possivelmente relacionado à infecção prévia pelo vírus Zika, Região Metropolitana do Recife, Pernambuco, Brasil, 2015." *Epidemiologia e Serviços de Saúde* 27(2): e2017039. <https://doi.org/10.5123/S1679-49742018000200016>.
- Olshansky, S. J., and L. Hayflick. 2017. "The Role of the WI-38 Cell Strain in Saving Lives and Reducing Morbidity." *AIMS Press* 4(2): 127–138. <https://doi.org/10.3934/publichealth.2017.2.127>.
- Orenstein, W. A., M. J. Papania, and M. E. Wharton. 2004. "Measles Elimination in the United States." *The Journal of Infectious Diseases* 189(s1): S1–S3. <https://doi.org/10.1086/377693>.
- Phadke, V. K., R. A. Bednarczyk, D. A. Salmon, and S. B. Omer. 2016. "Association Between Vaccine Refusal and Vaccine-Preventable Diseases in the United States: A Review of Measles and Pertussis." *JAMA* 315(11): 1149–58. <https://doi.org/10.1001/jama.2016.1353>.
- Principi, N., and S. Esposito. 2018. "Vaccine-preventable diseases, vaccines and Guillain-Barre' syndrome." *Vaccine.* <https://doi.org/10.1016/j.vaccine.2018.05.119>.
- Reichert, T. A., et al. 2001. "The Japanese Experience with Vaccinating Schoolchildren against Influenza." *New England Journal of Medicine* 344(12): 889–896. <https://doi.org/10.1056/NEJM200103223441204>.
- Roush, S. W., et al. 2007. "Historical Comparisons of Morbidity and Mortality for Vaccine-Preventable Diseases in the United States." *JAMA* 298(18): 2155. <https://doi.org/10.1001/jama.298.18.2155>.
- Rubin, L. G., et al. 2014. "2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host." *Clinical Infectious Diseases* 58(3): e44–e100. <https://doi.org/10.1093/cid/cit684>.
- Silvers L.E., et al. 2001. "The epidemiology of fatalities reported to the Vaccine Adverse Event Reporting System 1990–1997." *Pharmacoepidemiology and Drug Safety* 10(4): 279–285. <https://doi.org/10.1002/pds.619>.
- Sobh, A., and F. A. Bonilla. 2016. "Vaccination in Primary Immunodeficiency Disorders." *The Journal of Allergy and Clinical Immunology: In Practice* 4(6): 1066–1075. <https://doi.org/10.1016/j.JAIP.2016.09.012>.
- Taranger, J., et al. 2001. "Mass Vaccination of Children with Pertussis Toxoid—Decreased Incidence in Both Vaccinated and Nonvaccinated Persons." *Clinical Infectious Diseases* 33(7): 1004–1010. <https://doi.org/10.1086/322639>.
- Texas Department of State Health Services (TX DSHS). 2017. *Texas Vaccine Preventable Disease Epidemiology Update.* https://www.dshs.texas.gov/uploadedFiles/Content/Prevention_and_Preparedness/immunize/TIC%20-%202011-29_10-30_Texas-Vaccine-Preventable-Disease-Epidemiology-Update.pdf.
- TX DSHS. 2018a. *Exemption Information – School Immunizations.* <https://www.dshs.texas.gov/immunize/school/exemptions.aspx>.
- TX DSHS. 2018b. *Conscientious Exemptions Data – Vaccination Coverage Levels.* <https://www.dshs.texas.gov/immunize/coverage/Conscientious-Exemptions-Data.shtm>.

TX DSHS Immunization Unit. 2017. *2016–2017 Annual Report of Immunization Status of Students*. <https://dshs.texas.gov/immunize/coverage/schools/>.

Texas HB 2249. 2017. “Relating to requirements for and the transparency of epidemiological reports and immunization exemption information and reports.” <https://capitol.texas.gov/tlodocs/85R/billtext/html/SB01010L.htm>.

Texas HB 1124. 2017. “Relating to claiming an exemption from required immunizations for public school students.” <https://capitol.texas.gov/tlodocs/85R/billtext/html/HB01124L.htm>.

Thigpen, M. C., et al. 2011. “Bacterial Meningitis in the United States, 1998–2007.” *New England Journal of Medicine* 364(21): 2016–2025. <https://doi.org/10.1056/NEJMoa1005384>.

Thompson, W. W., et al. 2007. “Early Thimerosal Exposure and Neuropsychological Outcomes at 7 to 10 Years.” *New England Journal of Medicine* 357(13): 1281–1292. <https://doi.org/10.1056/NEJMoa071434>.

WHO (World Health Organization). n.d. *Module 2: Types of vaccine and adverse reaction*. http://www.who.int/vaccine_safety/initiative/tech_support/Part-2.pdf.

WHO. 2017. *Influenza*. <http://www.who.int/biologicals/vaccines/influenza/en/>.